179 related articles for article (PubMed ID: 38122917)
1. Oncogenic fusions: Targeting NTRK.
Hagopian G; Nagasaka M
Crit Rev Oncol Hematol; 2024 Feb; 194():104234. PubMed ID: 38122917
[TBL] [Abstract][Full Text] [Related]
2. NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.
Haratake N; Seto T
Clin Lung Cancer; 2021 Jan; 22(1):1-5. PubMed ID: 33272813
[TBL] [Abstract][Full Text] [Related]
3. NTRK fusions in lung cancer: From biology to therapy.
Harada G; Santini FC; Wilhelm C; Drilon A
Lung Cancer; 2021 Nov; 161():108-113. PubMed ID: 34563714
[TBL] [Abstract][Full Text] [Related]
4. NTRK gene fusion testing and management in lung cancer.
Repetto M; Chiara Garassino M; Loong HH; Lopez-Rios F; Mok T; Peters S; Planchard D; Popat S; Rudzinski ER; Drilon A; Zhou C
Cancer Treat Rev; 2024 Jun; 127():102733. PubMed ID: 38733648
[TBL] [Abstract][Full Text] [Related]
5. The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer.
Qin H; Patel MR
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328336
[TBL] [Abstract][Full Text] [Related]
6. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.
Lim KHT; Kong HL; Chang KTE; Tan DSW; Tan IBH; Mohamad F; Soh SY; Pang BN; Soo RA; Choo SP; Hsieh WS; Aung L
Asia Pac J Clin Oncol; 2022 Aug; 18(4):394-403. PubMed ID: 34806337
[TBL] [Abstract][Full Text] [Related]
7. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
8. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T
Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
[TBL] [Abstract][Full Text] [Related]
9. [NTRK Gene Fusions and Treatment in NTRK Fusion-Positive Solid Cancers].
Fukuda M; Naito Y
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1048-1050. PubMed ID: 36281593
[TBL] [Abstract][Full Text] [Related]
10. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
11. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence.
Ricciuti B; Brambilla M; Metro G; Baglivo S; Matocci R; Pirro M; Chiari R
Med Oncol; 2017 Jun; 34(6):105. PubMed ID: 28444624
[TBL] [Abstract][Full Text] [Related]
12. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
13. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
Laetsch TW; Hong DS
Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
[TBL] [Abstract][Full Text] [Related]
14. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
15. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk.
Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ
Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202
[TBL] [Abstract][Full Text] [Related]
16. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
Blauel ER; Laetsch TW
Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
[TBL] [Abstract][Full Text] [Related]
17. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
18. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
[TBL] [Abstract][Full Text] [Related]
20. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]